PTC Therapeutics, Inc. announced it has entered into an amendment to its royalty purchase agreement with Royalty Pharma Investments 2019 ICAV. Under the terms of the amendment, PTC sold its remaining interest in royalties related to Roche's Evrysdi® (risdiplam) to Royalty Pharma for $240 million in upfront cash. The agreement also includes provisions for three potential additional payments of $20 million each, contingent on certain sales-based royalty payment thresholds being met in 2027, 2028, and 2029. Following this transaction, Royalty Pharma now owns 100% of the royalty interest, and PTC Therapeutics retains no further royalty rights under the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-124837), on December 29, 2025, and is solely responsible for the information contained therein.